(Q36821702)

English

A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer

scientific article published on 12 April 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

16 August 2017

A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer (English)

1 reference

Europe PubMed Central

16 August 2017

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

10

object named as

Jose Baselga

1 reference

Europe PubMed Central

16 August 2017

1

object named as

Shanu Modi

1 reference

Europe PubMed Central

16 August 2017

Joyce O'Shaughnessy

9

object named as

Joyce O'Shaughnessy

1 reference

Europe PubMed Central

16 August 2017

4

object named as

Nancy U Lin

1 reference

Europe PubMed Central

16 August 2017

2

object named as

Cristina Saura

1 reference

Europe PubMed Central

16 August 2017

author name string

Charles Henderson

3

1 reference

Europe PubMed Central

16 August 2017

Reshma Mahtani

5

1 reference

Europe PubMed Central

16 August 2017

Jill Goddard

6

1 reference

Europe PubMed Central

16 August 2017

Eduardo Rodenas

7

1 reference

Europe PubMed Central

16 August 2017

Clifford Hudis

8

1 reference

Europe PubMed Central

16 August 2017

language of work or name

0 references

publication date

12 April 2013

1 reference

Europe PubMed Central

16 August 2017

Breast Cancer Research and Treatment

1 reference

Europe PubMed Central

16 August 2017

139

1 reference

Europe PubMed Central

16 August 2017

107-113

1 reference

Europe PubMed Central

16 August 2017

1

1 reference

Europe PubMed Central

16 August 2017

copyright license

Creative Commons Attribution-NonCommercial 2.5 Generic

12 April 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

https://scigraph.springernature.com/pub.10.1007/s10549-013-2510-5

0 references

Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646160

29 September 2017

Geldanamycin selectively targets the nascent form of ERBB3 for degradation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646160

29 September 2017

Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646160

29 September 2017

The heat shock protein 90 inhibitor IPI-504 induces apoptosis of AKT-dependent diffuse large B-cell lymphomas.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646160

29 September 2017

Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646160

29 September 2017

Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646160

29 September 2017

Heat shock protein 90: a potential therapeutic target in leukemic progenitor and stem cells harboring mutant BCR-ABL resistant to kinase inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646160

29 September 2017

Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646160

29 September 2017

Dose scheduling--Herceptin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646160

29 September 2017

HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646160

5 September 2018

Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646160

5 September 2018

Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel

1 reference

https://pubmed.ncbi.nlm.nih.gov/23580070

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23580070

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23580070

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10549-013-2510-5

1 reference

Europe PubMed Central

16 August 2017

release_incef5dlanetde4376h7twyuka

1 reference

https://api.fatcat.wiki/v0/release/incef5dlanetde4376h7twyuka

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

16 August 2017

1 reference

Europe PubMed Central

16 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36821702&oldid=2117036194"